Sobi signs licensing agreement with Affibody for IL-1
(Thomson Reuters ONE) -
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that it has exercised
its option to sign a licensing agreement with Swedish biotech company Affibody
AB for the development of novel treatments for inflammatory diseases where
interleukin-1 (IL-1) is involved.
In 2012, Sobi signed a research collaboration agreement with Affibody, with an
option to enter into exclusive licensing arrangements within IL-1. The research,
which has been based on Affibody's proprietary technology, focuses on key
proteins involved in the regulation of human immune and inflammatory processes.
"We are excited by the opportunities that this research collaboration offers,"
says Stephen James, Vice President, Head of Drug Design and Development at Sobi.
"The continued expansion of our early stage pipeline is one of our main
objectives this year and this will further strengthen our presence in the
inflammation field and may provide additional opportunities to address the unmet
medical needs in auto-inflammatory diseases."
"We are very pleased to sign a licensing agreement with Sobi," says David
Bejker, CEO of Affibody. "Together we have been exploring the use of the
Affibody® technology in the field of inflammatory and autoimmune diseases and we
are excited to continue this development."
An increasing body of evidence suggests that IL-1 is a key mediator of
inflammation and driver of auto-inflammatory diseases in both adults and
children. This offers a good strategic fit with Sobi's commercial focus on
Inflammation as one of three key therapeutic areas, and with Sobi's strategic
biologics development competence and capabilities.
---
About interleukin-1 (IL-1)
The interleukin-1 family is a group of pro-inflammatory cytokines that play a
central role in the regulation of immune responses in the human body. The
cytokines are produced by different cells such as macrophages, monocytes and
fibroblasts, and via binding to cellular IL-1 receptors they participate in
acute and chronic inflammatory reactions. In addition, the IL-1 system is also
involved in several other biological functions, such as metabolic and
hematopoietic activities. IL-1 has emerged as therapeutic target for an
expanding number of auto-inflammatory diseases where inhibition of IL-1 activity
may form the basis for novel treatments.
About Affibody
Affibody is a Swedish biotech company focused on developing next generation
biopharmaceuticals based on its unique proprietary technology platforms:
Affibody® molecules and Albumod(TM). Affibody is developing a portfolio of
innovative drug projects and, in addition, offers the half-life extension
technology, Albumod(TM), for outlicensing. The company is currently developing
four proprietary programs. The first three are therapeutic programs that targets
prevention of Alzheimer's disease, autoimmune diseases, and psoriasis
respectively. The fourth program is a diagnostic imaging program that is
directed primarily towards metastatic breast cancer. Affibody has also ongoing
commercial relationships with several companies including Abclon, Biotest,
Daewoong, Daiichi Sankyo, GE Healthcare, MedImmune, Nordic Nanovector, and Sobi.
More information is available at www.affibody.se.
About Sobi(TM)
Sobi(TM) is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of speciality and rare disease products for partner companies across
Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion
(USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed on
NASDAQ Stockholm.
For more information please contact
Media relations Investor relations
Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor
Communications Relations
T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135
oskar.bosson(at)sobi.com jorgen.winroth(at)sobi.com
019e_Affibody_licensing agreement:
http://hugin.info/134557/R/2005807/741007.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via GlobeNewswire
[HUG#2005807]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="ALX Uranium Acquires the North and South Carter Corridor PropertiesDatum: 22.04.2016 - 08:00 Uhr
Sprache: Deutsch
News-ID 465823
Anzahl Zeichen: 5427
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 236 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sobi signs licensing agreement with Affibody for IL-1"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
